UK
Health analytics
Medical and public affairs
Aging populations, living with more multi-morbid diseases, combined with constrained healthcare budgets, are placing unprecedented demand on our modern-day health systems. At the same time, inequalities in outcomes across populations are worsening in many parts of the globe.
As key partners to the system, it's critical that life sciences can cut through this complexity and bridge the gap between their business priorities and the needs of their healthcare system stakeholders.
Through our ability to bridge clinical, medical and commercialization as part of medical and public affairs, we empower teams to identify and act on opportunities for health system transformation, as well as communicate the value your intervention can bring.
Health system leaders face increasingly complex challenges
As medical, scientific and public affairs leaders it is critical that you can communicate the value of your intervention within this context. As well, aligning the priorities of your business with those of your key stakeholders is crucial.
We help clients bridge the gap between life sciences and the healthcare system by equipping Medical and Public Affairs teams with strategic expertise and tools to engage and drive change.
We use our analytic strengths to cut through the noise of large health data sets to identify the insights that are most relevant for decision-making. Together with our team’s deep expertise, this means we can support to generate compelling evidence and translate it into meaningful change. In the context of ever-changing policy and regulation, we stay on top of key market trends and can provide you with assurance on your planned activities.
We lead the market in identifying solutions for tomorrow’s challenges for patients, health systems and our clients
We work with our medical and public affairs clients across three key areas:
- Data visualization and bespoke dashboards: Using our expertise in informatics, data engineering, and web development to integrate and visualize diverse real-world datasets to support engagement and decision-making.
- Compelling communications: Leveraging our vast clinical and scientific experience to generate persuasive engagement pieces, including manuscripts, abstracts, and presentations, to help you engage and influence the wider scientific and medical community.
- Stakeholder engagement strategy and execution: Combining innovative approaches with our network of partners and collaborators to help you identify and act on opportunities to drive change to improve population health which are also aligned with your business objectives.
Medicines Nexus™
Prescription analytics platform
Our innovative prescription analytics platform delivering cutting-edge insights into the medicines market.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
Get in touch
Contact us to learn more about how we can provide clarity and insight in today’s increasingly complex life sciences and healthcare environment.
